The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Top Cited Papers
Open Access
- 1 January 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 12 (2), R63
- https://doi.org/10.1186/ar2978
Abstract
The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8.0 mg/dL in a six-month trial. Subjects (n = 2,269) were randomized to febuxostat 40 mg or 80 mg, or allopurinol 300 mg (200 mg in moderate renal impairment). Endpoints included the proportion of all subjects with sUA <6.0 mg/dL and the proportion of subjects with mild/moderate renal impairment and sUA <6.0 mg/dL. Safety assessments included blinded adjudication of each cardiovascular (CV) adverse event (AE) and death. Comorbidities included: renal impairment (65%); obesity (64%); hyperlipidemia (42%); and hypertension (53%). In febuxostat 40 mg, febuxostat 80 mg, and allopurinol groups, primary endpoint was achieved in 45%, 67%, and 42%, respectively. Febuxostat 40 mg UL was statistically non-inferior to allopurinol, but febuxostat 80 mg was superior to both (P < 0.001). Achievement of target sUA in subjects with renal impairment was also superior with febuxostat 80 mg (72%; P < 0.001) compared with febuxostat 40 mg (50%) or allopurinol (42%), but febuxostat 40 mg showed greater efficacy than allopurinol (P = 0.021). Rates of AEs did not differ across treatment groups. Adjudicated (APTC) CV event rates were 0.0% for febuxostat 40 mg and 0.4% for both febuxostat 80 mg and allopurinol. One death occurred in each febuxostat group and three in the allopurinol group. Urate-lowering efficacy of febuxostat 80 mg exceeded that of febuxostat 40 mg and allopurinol (300/200 mg), which were comparable. In subjects with mild/moderate renal impairment, both febuxostat doses were more efficacious than allopurinol and equally safe. At the doses tested, safety of febuxostat and allopurinol was comparable. NCT00430248.This publication has 46 references indexed in Scilit:
- We can make gout management more successful nowCurrent Opinion in Rheumatology, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IIArthritis & Rheumatism, 2007
- Lowering serum uric acid levels: What is the optimal target for improving clinical outcomes in gout?Arthritis Care & Research, 2007
- The changing epidemiology of goutNature Clinical Practice Rheumatology, 2007
- Epidemiology of Crystal ArthropathyRheumatic Disease Clinics of North America, 2006
- Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population.2004
- GoutThe New England Journal of Medicine, 2003
- Epidemiology of gout: is the incidence rising?2002
- Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic goutArthritis Care & Research, 2002
- Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?2001